Ready-to-Use Control Determines Linearity for Special Diabetes Tests

By LabMedica International staff writers
Posted on 14 Apr 2015

A new addition to clinical lab quality control products simulates human patient serum samples for the purpose of determining linearity, calibration verification, and verification of reportable range for special diabetes tests.

The Linearity LQ Special Diabetes from AUDIT MicroControls, Inc. (Eatonton, GA, USA) is an assayed quality-control material consisting of 5 distinct levels that demonstrate a linear relationship to each other when assayed for C-peptide, fructosamine, and insulin. It is a ready-to-use liquid product with open vial stability of 7 days when stored at 2–8 °C.

Image: The new ready-to-use “Linearity LQ Special Diabetes” is an assayed quality-control material consisting of 5 distinct levels that demonstrate a linear relationship to each other when assayed for C-peptide, fructosamine, and insulin (Photo courtesy of AUDIT MicroControls).

AUDIT MicroControls provides “Auditor QC,” a free on-line, real-time data reduction program that offers Levey-Jennings charts and peer group analysis for daily quality control product users, as well as linearity graphs and peer group analysis. Report results are given immediately in an inspector friendly format and stored on the Auditor QC website for convenient future reference.

AUDIT is a total solution in daily quality controls and calibration verification materials, providing high-quality products, easy-to-use data management tools, and personalized service. Synergistic partnership with leading manufacturer and supplier Aalto Scientific enables AUDIT to offer significant cost savings and a broad line of superior solutions that address challenges faced by today’s clinical labs.

Related Links:
AUDIT MicroControls
Linearity LQ Special Diabetes